721970-37-2

Basic information

• Product Name: N-Methyl Moxifloxacin
• Synonyms: N-Methyl Moxifloxacin;1-cyclopropyl-6,8-difluoro-7-((4aS,7aS)-1-Methyloctahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;1-cyclopropyl-6-fluoro-8-methoxy-7-((4aS,7aS)-1-methyloctahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;N-Methyl Moxifloxacin Hydrochloride 2;1-cyclopropyl-6-fluoro-8-methoxy-7-((4aS,7aS)-1-methyl-octahydropyrrolo[3,4-b]pyridin-6-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-1-methyl-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid;1-cyclopropyl-6-fluoro-8-methoxy-7-((4aS,7aS)-1-2-methyloctahydro-6Hpyrrolo[3,4-b]pyridin-6-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
• CAS NO: 721970-37-2
• Molecular Formula: C22H27ClFN3O4
• Molecular Weight: 451.9188832
• Product Categories: Chiral Reagents;Impurity;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 721970-37-2.mol

Chemical Properties

• Boiling Point: 616.5±55.0 °C(Predicted)
• Appearance: /
• Density: 1.384±0.06 g/cm3(Predicted)
• Storage Temp.: Hygroscopic, Refrigerator, Under inert atmosphere
• Solubility: Chloroform (Slightly), DMSO (Sparingly, Sonicated), Methanol (Slightly)
• PKA: 6.43±0.50(Predicted)
• Stability: Hygroscopic
• CAS DataBase Reference: N-Methyl Moxifloxacin(CAS DataBase Reference)
• NIST Chemistry Reference: N-Methyl Moxifloxacin(721970-37-2)
• EPA Substance Registry System: N-Methyl Moxifloxacin(721970-37-2)

Safety Data

• Hazardous Substances Data: 721970-37-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-Methyl Moxifloxacin is used as an impurity in the synthesis and production of Moxifloxacin (M745000), a fluorinated quinolone antibacterial. Its presence in the manufacturing process may affect the overall quality, efficacy, and safety of the final product. Therefore, understanding and controlling the levels of N-Methyl Moxifloxacin is crucial for ensuring the therapeutic benefits and minimizing potential side effects of Moxifloxacin.
Additionally, due to its structural similarity to Moxifloxacin, N-Methyl Moxifloxacin may also be investigated for its potential as a standalone antibacterial agent or in combination with other drugs to enhance their efficacy against resistant bacterial strains. Further research would be required to explore these possibilities and determine the specific application reasons for N-Methyl Moxifloxacin in the pharmaceutical industry.

Upstream product

• 50-00-0 formaldehyd 
• 151096-09-2 moxifloxacin 
• 1420107-30-7 C₂₃H₂₈FN₃O₄ 
• 151213-40-0 (1S,6S)-2,8-diazabicyclo[4.3.0]nonane 
• 112811-72-0 1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid 

Relevant articles and documents

Preparation method of quinolone carboxylic acid derivative or phthalazinone carboxylic acid derivative

The invention belongs to the field of pharmaceutical chemicals, relates to a preparation method of a quinolone carboxylic acid derivative or a phthalazinone carboxylic acid derivative, and particularly relates to a preparation method of a 7-substituted-3-quinolone carboxylic acid derivative or a 7-substituted-1,5-phthalazinone carboxylic acid derivative. The preparation method comprises the following steps: (1) in an organic solvent, carrying out coupling reaction on a boron chelate II and organic amine III in the presence of an organosilicon compound to obtain a compound IV; and (2) mixing the compound IV with hydrochloric acid, and then filtering and separating the precipitated compound I. Compared with conventional methods, the preparation method provided by the invention has the advantages that the conditions are milder, the hydrolysis of the substrate quinoline carboxylic acid boric acid ester can be reduced, and meanwhile, the influence of a byproduct HF on the product purity is avoided. The method is high in yield and high in purity; compared with the traditional alkali, the organic silicon is more suitable for industrial preparation of the 7-substituted-3-quinolone carboxylic acid derivative or the 7-substituted-1,5-phthalazinone carboxylic acid derivative.

N-methylmoxifloxacin aldehyde thiosemicarbazone derivative, and preparation method and application thereof

The invention discloses an N-methylmoxifloxacin aldehyde thiosemicarbazone derivative, and a preparation method and an application thereof. The N-methylmoxifloxacin aldehyde thiosemicarbazone derivative has a structure as shown in a general formula I in the specification. In the general formula I, R is selected from the group consisting of an H atom, or a hydrocarbyl group with 1 to 5 carbon atoms or a cyclopropyl group. The N-methylmoxifloxacin aldehyde thiosemicarbazone derivative provided by the invention realizes combination of three advantage pharmacophores like a fluoroquinolone skeleton, Schiff base imine and thiourea, thereby adding the antitumor activity of a novel compound, reducing the toxic and side effects on normal cells, and being able to be used as an antitumor active substance to develop an antitumor drug with a novel structure.

Process for the preparation of moxifloxacin hydrochloride and intermediates thereof

The present invention refers to a process for the preparation of Moxifloxacin hydrochloride through the synthesis of Moxifloxacin salts with sulfonic acids.

MOXIFLOXACIN HYDROCHLORIDE COMPOUNDS AND INTERMEDIATES AND METHODS FOR MAKING SAME

Methods for producing moxifloxacin hydrochloride compounds having very low levels of impurities are provided. Compounds produced using such methods and pharmaceutical compositions including such compounds are also provided.